Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.80 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | KRAS | P01116 | 5/20 | 0.75 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.74 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.68 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.63 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.63 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932313 | 1.00 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL29399391 | 1.00 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL20277520 | 1.00 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL20282956 | 1.00 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL20277656 | 1.00 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL29429843 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL851357 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL21067722 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL18769114 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 0.94 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | claimed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-114945384-A | Highly sialylated multimeric binding molecules | IGM生物科学股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-107501370-A | The synthesis of the anti-reverse phosphorothioate analogs of mRNA cap and purposes | 路易斯安那州州立大学及农业机械学院管理委员会 | 2017-12-22 | — | — | CN | disclosed |
| EP-2049127-B1 | N-METHANOCARBA DERIVATIVES TO TREAT CARDIAC DISEASES | UNIV CONNECTICUT (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8410078-B2 | Composition and methods to treat cardiac diseases | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120329709-A1 | PRODUCTION OF GLYCOPROTEINS | MOMENTA PHARMACEUTICALS, INC. | 2012-12-27 | — | — | US | disclosed |
| EP-2435577-A2 | PRODUCTION OF GLYCOPROTEINS | Momenta Pharmaceuticals, Inc. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138502-A2 | PRODUCTION OF GLYCOPROTEINS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-1203007-A4 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS | GILEAD SCIENCES INC (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008807-A1 | Novel signaling pathway for the production of inflammatory pain and neuropathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-01-09 | — | — | US | disclosed |
| US-20020150536-A1 | Nucleic acid ligands to integrins | GILEAD SCIENCES, INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1203007-A1 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS | GILEAD SCIENCES, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1071434-A4 | CNRE BINDING FACTORS AND USES THEREOF | BRIGHAM & WOMENS HOSPITAL (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6331394-B1 | CONTACTING CANDIDATE MIXTURE OF NUCLEIC ACIDS WITH INTEGRIN, WHEREIN NUCLEIC ACIDS HAVING INCREASED AFFINITY TO INTEGRIN RELATIVE TO CANDIDATE MIXTURE MAY BE PARTITIONED FROM REMAINDER OF MIXTURE, PARTITIONING, AMPLIFIFYING | GILEAD SCIENCES, INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001009159-A1 | NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS | GILEAD SCIENCES, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1071434-A1 | CNRE BINDING FACTORS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| US-6166076-A | Taste enhancing food additives | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2000-12-26 | — | — | US | disclosed |
| WO-1999055343-A1 | CNRE BINDING FACTORS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329709-A1 | PRODUCTION OF GLYCOPROTEINS | FUT4, SIGLEC7, ST6GAL1 | TGM2 320/4885NT5E 1054/4885KRAS 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.